Head-to-head · WeighScore
Hims & Hers vs Trillium Meds
The verdict
Hims & Hers takes it — 81/100 to 69.4/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | Trillium Meds |
|---|---|---|
| WeighScore | 81/100 | 69.4/100 |
| Grade | B− | C |
| Scorecard rank | #36 | #124 |
| Semaglutide | $199/mo | $119/mo (3-month plan, compounded) |
| Tirzepatide | Not disclosed | $199/mo (3-month plan, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #36 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #124 · C
Strengths
- LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
- All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
- Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
- Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
- Klarna and Affirm financing available; pause anytime with no long-term commitment required
Where it loses points
- No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
- Small single-operator platform may limit capacity and support consistency as patient volume grows
- Compounded medications are not FDA-approved; newer platform with limited long-term public track record
- Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
- No live video consult disclosed; async intake-form-based provider review by external licensed provider network
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.